Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis

被引:3
|
作者
Zhang, Suo [1 ,2 ]
Chen, Yu-Lan [1 ]
Liu, Cui-Lian [1 ]
Xie, Jing-Yi [1 ]
Sun, Bao-Dong [1 ]
Liu, Dong-Zhou [1 ]
机构
[1] Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Rheumatol & Immunol, Jinan Univ,Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen, Peoples R China
[2] Shenzhen Second Peoples Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
IgA nephropathy; systemic autoimmune myopathies; dermatomyositis; anti- transcription intermediary factor-1 gamma antibody; dermatomyositis-specific antibodies; RENAL INVOLVEMENT; POLYMYOSITIS; AUTOANTIBODIES; SPECTRUM; GLOMERULONEPHRITIS; CLASSIFICATION; DISEASE; RISK; LOCI;
D O I
10.3389/fimmu.2022.757802
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis characterized by IgA deposits in the mesangial area of glomeruli. Connective tissue disorders are some of the most frequent causes of secondary IgAN. Nevertheless, IgAN rarely occurs in systemic autoimmune myopathies (SAMs). The present case study reports on a 58-year-old patient with dermatomyositis with positive anti-transcription intermediary factor (TIF)-1 gamma antibodies who was diagnosed with IgAN during standard immunosuppressive therapy. Moreover, we have made a systematic review regarding the association of SAMs and IgAN. To the best of the authors' knowledge, this is the first case study describing a patient with anti-TIF1 gamma antibody-positive dermatomyositis who developed IgAN, which demonstrates a potential relationship between anti-TIF1 gamma-positive dermatomyositis and IgAN. It is important for clinicians to be aware of the possibility of renal involvement in patients with SAMs, even in those with anti-TIF1 gamma-positive dermatomyositis.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] A case of anti-Mi-2 antibody-positive dermatomyositis associated with malignant lymphoma
    Ohashi, Masafumi
    Takagi, Hajime
    Hayakawa, Masaya
    Hamaguchi, Yasuhito
    Seishima, Mariko
    MODERN RHEUMATOLOGY CASE REPORTS, 2019, 3 (01) : 62 - 66
  • [22] The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis
    Aussy, Audrey
    Freret, Manuel
    Gallay, Laure
    Bessis, Didier
    Vincent, Thierry
    Jullien, Denis
    Drouot, Laurent
    Jouen, Fabienne
    Joly, Pascal
    Marie, Isabelle
    Meyer, Alain
    Sibilia, Jean
    Bader-Meunier, Brigitte
    Hachulla, Eric
    Hamidou, Mohammed
    Hue, Sophie
    Charuel, Jean-Luc
    Fabien, Nicole
    Viailly, Pierre-Julien
    Allenbach, Yves
    Benveniste, Olivier
    Cordel, Nadege
    Boyer, Olivier
    Amoura, Zahir
    Aouizerate, Jessie
    Authier, Francois-Jerome
    Benhamou, Ygal
    Benichou, Jacques
    Cherqaoui, Bilade
    Chosidow, Olivier
    Debarbieux, Sebastien
    Fardet, Laurence
    Graveleau, Julie
    Kahn, Jean-Emmanuel
    Langlois, Vincent
    Levesque, Herve
    Martin, Jerome
    Martis, Nihal
    Masseau, Agathe
    Musset, Lucile
    Neel, Antoine
    Queyrel-Moranne, Viviane
    Terrier, Benjamin
    Vinzio, Stephan
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (08) : 1360 - 1370
  • [23] Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis
    Motegi, Sei-ichiro
    Sekiguchi, Akiko
    Ikeuchi, Hidekazu
    Sakairi, Toru
    Ogawa, Hiroomi
    Fujii, Takaaki
    Sohda, Makoto
    Yajima, Toshiki
    Ida, Shota
    Takayasu, Yukihiro
    Shimoda, Yuki
    Hiromura, Keiju
    Saeki, Hiroshi
    Shirabe, Ken
    Chikamatsu, Kazuaki
    Yokoo, Hideaki
    Oyama, Tetsunari
    Ishikawa, Osamu
    JOURNAL OF DERMATOLOGY, 2020, 47 (12) : 1395 - 1402
  • [24] Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation
    Aggarwal, Rohit
    Oddis, Chester V.
    Goudeau, Danielle
    Fertig, Noreen
    Metes, Ilinca
    Stephens, Chad
    Qi, Zengbiao
    Koontz, Diane
    Levesque, Marc C.
    RHEUMATOLOGY, 2014, 53 (03) : 433 - 437
  • [25] SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-y, and Point Mutation in the Transcription Intermediary Factor 1-y Coding Gene: A Case Report
    Arnon, Johnathan
    Elia, Anna
    Nevo, Yuval
    Lossos, Alexander
    Nechushtan, Hovav
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (09):
  • [26] Clinical utility of anti-Ro52 antibody confirmation in anti-MDA5 antibody-positive dermatomyositis: A case report
    Kodera, Hitoshi
    Hirano, Reina
    Akiyama, Masahiro
    Matsumoto, Yoshifuji
    MODERN RHEUMATOLOGY CASE REPORTS, 2024, 8 (02) : 291 - 295
  • [27] Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis
    Ikeda, Nobuaki
    Yamaguchi, Yukie
    Kanaoka, Miwa
    Ototake, Yasushi
    Akita, Asami
    Watanabe, Tomoya
    Aihara, Michiko
    JOURNAL OF DERMATOLOGY, 2020, 47 (05) : 490 - 496
  • [28] Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis
    Kato, Toshio
    Ito, Satoru
    Tsuzuki, Toyonori
    Watanabe, Daisuke
    Kubo, Akihito
    Yamaguchi, Etsuro
    RESPIROLOGY CASE REPORTS, 2019, 7 (04):
  • [29] Anti-nuclear matrix protein 2 antibody-positive amyopathic dermatomyositis presenting in a patient with prostate cancer: A case report
    Shan, Divya M.
    Gupta, Neha
    Ortega-Loayza, Alex G.
    Shea, Sofia
    Nandan, Abhishek
    CLINICAL CASE REPORTS, 2024, 12 (05):
  • [30] Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis
    Shimizu, Kyoko
    Kobayashi, Tadahiro
    Kano, Miyu
    Hamaguchi, Yasuhito
    Takehara, Kazuhiko
    Matsushita, Takashi
    JOURNAL OF DERMATOLOGY, 2020, 47 (01) : 64 - 68